

Time after heat shock (h)

HS>rpr

Fig. 1

positive correlation	negative correlation
cAMP	Adriamycin
Podophyllotoxin	Alsterpaullone
Hydrocortisone	Mitoxantrone
Furazolidone	Pyrazinamide
Anisomycin	Cephapirin
Colistin	Dextromethorphan
Bumetanide	Riboflavin
Terazosin	Rotenone
Josamycin	Apomorphine
Edrophonium chloride	Doxepin
Fluticasone	Nicergoline
	Hycanthone
	Benzydamine
	Phenindione

Fig. 2


P=0.001
60
40
20
0
Survival(%)
Control
Terazosin
Fluticasone
Alsterpaullone
Hydrocortison
HS>reaper

Fig. 3


P<0.001
100
80
60
40
20
0
Annexin V
Positive cells(%)
Control
LPS+IFN-γ
LPS+IFN-γ
+Terazosin

Fig. 4


a
100
80
60
40
20
0
Survival(%)
LPS+Terazosin
(0.4mg/kg, 1.5h)
N=25
LPS N = 27
0 24 48 72 96 120 144 16
Time after LPS shock(h)
b
Vehicle
LPS1
LPS2
LPS+T1
LPS+T2
500bp
400bp
300bp
200bp
100bp

Fig. 5


100
80
60
40
20
0
Survival(%)
P = 0.529
LPS + T (0.4mg/kg, 12 h) N = 10
LPS N = 9
0 24 48 72 96 120 144 168
Time after LPS shock(h)

Fig. 6


100
80
60
40
20
0
Survival(%)
Escherichia coli+Terazosin
(0.4mg/kg，1.5h) N=5
P=0.073
Escherichia coli N=6
0 24 48 72 96 120 144 168
Time after Escherichia coli injection (h)

Fig. 7



Fig. 8


100
80
60
40
20
0
Survival(%)
T (0.08 mg/kg, 1.5 h, 24h) N=15
T(0.08 mg/kg + Co-Am (30 mg/kg, 1.5 h, 24h)N = 7
Vehide, N=14
Co-Am (30 mg/kg) N = 7
0
24
48
72
96
120
144
168
Time after CLP (h)

Fig. 9


Control
LPS+IFN-γ
LPS+IFN+ Terazosin
Cleaved Caspase 3
β-Actin

Fig. 10



Fig. 11


a
Naked beads
Bait beads + competitor
Bait beads
55kd
43kd
pgk1
b
Naked beads
Bait beads + competitor
Bait beads
55kd
43kd
pgk1

Fig. 12


0.025
0.02
0.015
0.01
0.005
0
Activity units of pgk1
0
0.05
0.1
0.2
0.4
Concentration of Terazosin(μM)

Fig. 13


Control
LPS+IFN-γ
%
Annexin V
Positive cells(%)
40
30
20
10
0
EGFP
pgk1

Fig. 14


pgk1 infected, N=7 P=0.072
EGFP infected, N=6
Survival(%)
100
80
60
40
20
0
0
24
48
72
96
120
144
168
Time after CLP (h)

Fig. 15


Before drug admin.
After drug admin.
Serum glucose
(mmol/L)
12
10
8
6
4
2
0
**
Saline
Terazosin

Fig. 16


20
15
%
10
infarct volume
5
0
*
I/R
I/R+
Terazosin

Fig. 17